Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

Assurex Health Inc.104 enrolled

Overview

Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability, decreased productivity, and missed work may in part derive from a mismatch between optimal, and actual, medications prescribed. The present one year retrospective study seeks to evaluate the indirect and direct healthcare costs for 96 patients with a DSM-IV-TR depressive or anxiety disorder, in relation to an interpretive reporting system designed to predict antidepressant responses based on DNA variations in cytochrome P450 genes (CYP2D6, CYP2C19, CYP1A2), the serotonin transporter gene (SLC6A4), and the serotonin 2A receptor (5HTR2A) genes.

Study Type

OBSERVATIONAL

Enrollment

104

Conditions

Depression Anxiety

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Major Depressive Disorder * Dysthymic Disorder * Depressive Disorder NOS * Obsessive Compulsive Disorder (OCD) * Generalized Anxiety Disorder * Panic Disorder * Anxiety Disorder NOS * Post-Traumatic Stress Disorder (PTSD) * Social Phobia Exclusion Criteria: * Bipolar Disorder * Schizophrenia * Schizoaffective Disorder * Previous pharmacogenomic testing

Locations (1)

Outcomes

Primary Outcomes

Number of Outpatient Visits

Number of outpatient healthcare visits during study window

Time frame: During the one year study window (April 1, 2010 to April 1, 2011)

Secondary Outcomes

Number of Medical Absence Days

Number of medical absence days during study window

Time frame: During the one year study window (April 1, 2010 to April 1, 2011)

Number of Disability Claims

Number of disabiity claims during study window

Time frame: During the one year study window (April 1, 2010 to April 1, 2011)